Alaminos M, Gerald WL, Cheung NK. Prognositic value of MYCN and ID2 overexpression in neuroblastoma. Pediatric Blood & Cancer 45: 909-915. [PubMed]

Mora J, Gerald WL, Qin J, Cheung NK. Evolving significance of prognostic markers associated with treatment improvement in stage 4 neuroblastoma. Cancer 94:2756-2765, 2002.[PubMed]

Mora J, Gerald WL, Qin J, Cheung NK. Molecular genetics of neuroblastoma and the implications for clinical management. A review of the MSKCC experience. Oncology 6:263-268, 2001.[PubMed]

Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N. Prognostic significance of EPHB6, EFNB2 and EFNB3 expressions in neuroblastoma. Medical and Pediatric Oncology 35:656-658, 2000.[PubMed]

Kramer K, Gerald W, LeSauteur L, Uri Saragovi H, Cheung NK. Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma. Clinical Cancer Research 2: 1361-1367, 1996.[PubMed]

Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NK. Monoclonal antibody to human TrkA: diagnostic and therapeutic potential in neuroblastoma. European Journal of Cancer 33: 2090-2091, 1997.[PubMed]

Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauter L, Saragovi HU. Correlation of MYCN amplification, TrkA and CD44 expression with clinical stage in 250 patients with neuroblastoma. European Journal of Cancer 33:2098-2100, 1997.[PubMed]

LeSauteur L, Cheung NK, Lisbona R, Saragovi HU. In vivo imaging of nerve growth factor receptors with small molecule analogs of nerve growth factor. Nature Biotechnology 14:1120-1122, 1996.[PubMed]